Codexis, Inc. Reports Second Quarter 2013 Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced financial results for the second quarter ended June 30, 2013.
“We continued to make significant progress with all of our value-driving business platforms in recent months,” said John Nicols, President and CEO of Codexis. “We continued to build on our core pharmaceutical business, expanding our pipeline opportunities through a collaboration with Purolite around immobilized enzymes and with the addition of a new head of sales and marketing.
Help employers find you! Check out all the jobs and post your resume.
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced financial results for the second quarter ended June 30, 2013.
“We continued to make significant progress with all of our value-driving business platforms in recent months,” said John Nicols, President and CEO of Codexis. “We continued to build on our core pharmaceutical business, expanding our pipeline opportunities through a collaboration with Purolite around immobilized enzymes and with the addition of a new head of sales and marketing.
Help employers find you! Check out all the jobs and post your resume.